VERA vs. TGTX, LNTH, NUVL, TLX, AXSM, ADMA, AKRO, PCVX, RYTM, and KRYS
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Vera Therapeutics vs. Its Competitors
TG Therapeutics (NASDAQ:TGTX) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.
TG Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of 10.13% compared to Vera Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat Vera Therapeutics' return on equity.
TG Therapeutics currently has a consensus price target of $40.80, indicating a potential upside of 14.57%. Vera Therapeutics has a consensus price target of $65.00, indicating a potential upside of 182.61%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than TG Therapeutics.
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, TG Therapeutics had 6 more articles in the media than Vera Therapeutics. MarketBeat recorded 8 mentions for TG Therapeutics and 2 mentions for Vera Therapeutics. TG Therapeutics' average media sentiment score of 1.17 beat Vera Therapeutics' score of 0.56 indicating that TG Therapeutics is being referred to more favorably in the media.
TG Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Summary
TG Therapeutics beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VERA) was last updated on 7/8/2025 by MarketBeat.com Staff
